92 Britannia Walk
About MeiraGTxMeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders.
CEO: Alexandria Forbes
CSO: Robin Ali
CDO: Stuart Naylor
COO: Richard Giroux
Please click here for clinical trial information.
25 articles with MeiraGTx
CEO to CEO: Tips for First-time Founders
1/11/2022BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders.
Clinical Catch-Up: December 6-10
12/13/2021There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
J&J indicated it will soon release Phase III data and could file for Emergency Use Authorization with the U.S. Food and Drug Administration by the end of the month.
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
BioSpace Global Roundup, March 5
3/5/2020Life sciences companies from across the globe provide updates on their businesses and pipelines.
BioSpace Global Roundup, Sept. 12
9/12/2019Companies and organizations from across Europe, Asia and North America share updates on their business and pipelines.
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc.
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
BioSpace Movers and Shakers Oct. 29
10/29/2018Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
Gene Therapy Company MeiraGTx Buys Vector Neurosciences for Its Phase II Parkinson's Product
10/9/2018MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.
Three Biotechs Announce IPOs
6/8/2018Three clinical-stage biotechnology companies announced initial public offerings (IPOs) today. Here’s a summary.
MeiraGTx Files for an $86 Million IPO
5/15/2018MeiraGTx has filed with the U.S. Securities and Exchange Commission (SEC) its intentions to launch an initial public offering (IPO).
MeiraGTx Announces AAV-RPGR Granted Fast Track Designation by U.S. FDA for Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiency
MeiraGTx Limited, a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene.
A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe.
MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate
MeiraGTx, a London and New York based gene therapy company, announced today the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to MeiraGTx’s gene therapy product candidate A002 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGB3 gene.
MeiraGTx Announces Gene Therapy Manufacturing Collaboration With Oxford Genetics
The collaboration will enable MeiraGTx and Oxford Genetics to develop novel AAV vectors, as well as packaging and producer cell lines to support the manufacturing needs of MeiraGTx's pipeline of gene therapy product candidates.
MeiraGTx Receives Rare Pediatric Disease Designation for A001 for the Treatment of Leber's Congenital Amaurosis and Treats First Pediatric Patient in Phase I/II Clinical Trial
The primary endpoint of the study is to determine the safety of the treatment. Secondary endpoints include improvement in visual function including a mobility maze, retinal function, retinal structure and quality of life measures.
Oxford Genetics Announces Adeno-Associated Virus Collaboration With MeiraGTx
The collaboration will enable Oxford Genetics and MeiraGTx to develop novel AAV vectors, as well as packaging and producer cell lines.
MeiraGTx Provides Clinical Trial Updates For X-Linked Retinitis Pigmentosa And Achromatopsia Gene Therapy Programs